Skip to main content

Advertisement

Table 1 Baseline characteristics of the study cases at enrollment from the different sites

From: Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania

Year Drug/site Enrolled numbers Age (years) Median (range) Sex (male) n (%) Temperature (°C) Mean (SD) Parasitaemia (μl) GM (range)
2011 ASAQ
 Ujiji 73 2.7 (0.2–5) 37 (50.7) 38.4 (1.3) 48,183 (1600–198,194)
 Kibaha 29 3.0 (1–5) 17 (58.6) 38.2 (1.1) 6162 (1034–80,000)
AL
 Muheza 32 2.0 (1–5) 18 (56.3) 37.9 (1.2) 24,400 (1680–160,457)
2012 AL
 Chamwino 26 5.0 (1–8) 13 (50.0) 38.1 (1) 8146 (1120–36,800)
 Kyela 44 3.0 (1–10) 20 (45.5) 38.1 (1.2) 32,741 (1680–180,800)
 Nagaga 62 3.0 (1–10) 30 (48.4) 38.3 (0.9) 22,368 (1040–149,382)
2015 AL
 Kyela 80 6.5 (0.6–60) 40 (50.0) 38.1 (1.3) 13,303 (640–84,480)
DHA-PQ
 Rufiji 82 10 (0.8–87) 44 (51.2) 37.6 (0.9) 12,007 (960–199,120)
  1. GM geometric mean, ASAQ artesunate/amodiaquine, AL artemether/lumefantrine, DHA-PQ dihydroartemisinin/piperaquine